Cureus

New Cases of Irregular Heartbeat Possibly Linked to Tirzepatide: A Case Report

Updated

Abstract

A 62-year-old woman developed new-onset atrial fibrillation after starting tirzepatide treatment.

  • Tirzepatide is used for type 2 diabetes and obesity but may be associated with rare cardiac rhythm disturbances.
  • The patient experienced palpitations, low blood pressure, and a rapid heart rate that required intensive medical intervention.
  • No underlying heart disease, electrolyte issues, or hormonal disorders were found during examination.
  • Atrial fibrillation did not return after stopping tirzepatide, suggesting a possible link between the medication and the arrhythmia.
  • Vigilance for cardiac arrhythmias is important when initiating new incretin-based therapies.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free